Is Homology Medicines (FIXX) Finally Worth Your Time? What Does B. Riley FBR Think?

September 7, 2018 - By Ash Maslow

Why Has B. Riley FBR Given Homology Medicines (FIXX) a $18.5 Price Target

The firm B. Riley FBR has today has started coverage on Homology Medicines (FIXX) shares, with a “Neutral” rating, while giving it the TP at $18.5.

Homology Medicines, Inc. (NASDAQ:FIXX) Ratings Coverage

Among 3 analysts covering Homology Medicines Inc (FIXX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Homology Medicines Inc has $3500 highest and $2700 lowest target. $31’s average target is 89.60% above currents $16.35 stock price. Homology Medicines Inc had 4 analyst reports since April 23, 2018 according to SRatingsIntel. The stock has “Buy” rating by Cowen & Co on Monday, April 23. The rating was initiated by BTIG Research with “Buy” on Tuesday, April 24. Bank of America initiated it with “Buy” rating and $2700 target in Monday, April 23 report.

The stock increased 2.44% or $0.39 during the last trading session, reaching $16.35. About 39,509 shares traded. Homology Medicines, Inc. (FIXX) has 0.00% since September 8, 2017 and is . It has underperformed by 12.57% the S&P500.

Analysts await Homology Medicines, Inc. (NASDAQ:FIXX) to report earnings on November, 12. After $-0.35 actual earnings per share reported by Homology Medicines, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company has market cap of $609.12 million. The Company’s proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. It currently has negative earnings. The company's various set of AAVHSCs allows firm to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities?gene editing and gene therapy.

More news for Homology Medicines, Inc. (NASDAQ:FIXX) were recently published by: Benzinga.com, which released: “Benzinga’s Top Upgrades, Downgrades For September 7, 2018” on September 07, 2018. Seekingalpha.com‘s article titled: “Premarket analyst action – healthcare” and published on September 07, 2018 is yet another important article.

Homology Medicines, Inc. (NASDAQ:FIXX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.